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The choice of drug therapy in pregnant patients suffering from vaginal infections is limited17
by the safety profile of the drug. Assuring the efficient topical therapy to avoid systemic18
absorption is considered the best therapy option. Chitosan-coated liposomes have been19
developed and optimized to assure localized therapy of clotrimazole. Chitosan was selected20
as mucoadhesive polymer both to prolong system’s retention at the vaginal site and act on21
biofilms responsible for high recurrence of infections. Sonicated liposomes were coated22
with chitosan in three different concentrations, namely 0.1, 0.3 and 0.6 % (w/v).23
Clotrimazole-containing (22 μg/mg lipid) chitosan-coated liposomes were in the size range 24 
of 100-200 nm. The in vitro release studies confirmed prolonged release of clotrimazole25
from both non-coated and chitosan-coated liposomes as compared to control. The ex vivo26
penetration experiments performed on the pregnant sheep vaginal tissue showed that coated27
liposomes assured increased clotrimazole tissue retention and reduced its penetration as28
compared to the control. Mucin studies revealed that the coating with lower chitosan29
concentration increased the system’s mucoadhesive potential, as compared to coating with30
higher concentrations. These results provide a good platform for further in vivo animal31
studies on mucoadhesive liposomes destined to localized vaginal therapy.32
33





Although the occurrence of vaginal infections in pregnancy is common, the choice of drug38
therapy is rather limited (das Neves et al., 2008). In particular, topical antifungal therapy is39
preferred due to the systemic toxicity of antifungal drugs (Chang et al., 2002). In pregnant40
patients, the two main therapy goals can be summarized as i) assuring the high local drug41
concentration with concomitant avoidance of systemic absorption and ii) prevention of42
infection recurrence (Vanić and Škalko-Basnet, 2013). We propose that coating of 43 
liposomal surfaces with chitosan can assure both of the goals. When vagina is the site of44
drug administration, it is also important that both the drug and corresponding delivery45
system are safe and non-irritating to the delicate vaginal mucosa (Woodrow et al., 2009).46
The selection of mucoadhesive polymer will be therefore based on its biodegradability,47
biocompatibility and confirmed mucoadhesivness. Chitosan fulfils all the above mentioned48
criteria (Bernkop-Schnürch and Dünnhaupt, 2012; Bhattarai et al., 2010). Moreover,49
chitosan as mucoadhesive polymer is suited for repeated adhesion, as it does not become50
inactivated after the first contact with mucus; no reduction in its mucoadhesiveness has51
been reported (Valenta, 2005). In respect to recurrence, it is now clear that bacterial52
biofilms play an important role, as the negatively charged polysaccharide matrix coats the53
bacteria in the biofilm and restricts the penetration of antimicrobial in deeper parts of54
biofilm. Recently, chitosan was proposed to be able to disrupt bacterial biofilms in vaginal55
environment more efficiently than other polymers (polycarbophil). Even more importantly,56
its anti-biofilm effect was found to be pH-independent (Kandimalla et al., 2013).57
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The mucoadhesiveness of chitosan-based delivery systems has been studied in various58
routes of drug administration (das Neves et al., 2011a; Gradauer et al., 2012; Sugihara et59
al., 2012; Takeuchi et al., 2001; Takeuchi et al., 2005; Wang et al., 2011); however, its60
potential in vaginal drug delivery was comparatively less studied (Valenta, 2005; Bonferoni61
et al., 2008; Kast et al., 2002; Perioli et al., 2008; Perioli et al., 2009; Berginc et al., 2014).62
Based on its confirmed mucoadhesiveness, it is reasonable to expect that chitosan-based63
delivery systems will be superior in vaginal drug delivery, as some recent studies on64
chitosan nanoparticles indicate (Meng et al., 2011).65
The success of non-invasive drug delivery via vaginal mucosa will be result of the interplay66
between the local vaginal environment, drug and physicochemical properties of drug carrier67
(Berginc et al., 2014). However, the interaction between drug delivery system and68
cervicovaginal mucus can affect the performance of drug nanocarrier, as the carrier must69
migrate through the vaginal or cervical fluid in order to deliver drug to the underlying70
mucosal surface (das Neves et al., 2012; Vanić and Škalko-Basnet, 2013). Vaginal mucosal 71 
tissue has relatively low turnover, which would be beneficial for prolonged residence time72
(Andrews et al., 2009). Vaginal absorption of drugs occurs in two main steps, namely the73
drug dissolution in vaginal lumen followed by the membrane penetration (Husain and74
Ahsan, 2005).75
As a model drug we selected clotrimazole, often prescribed in vulovaginal candidosis. Its76
local therapy is recommended to pregnant and breast-feeding patients, as well as to patients77




2. Materials and methods81
Materials82
Lipoid S 100 (PC, soybean lecithin, > 94 % phosphatidylcholine) was a generous gift from83
Lipoid GmbH, Ludwigshafen, Germany. Chitosan, low Mw (Brookfield viscosity 20.00084
cps, degree of deacetylation (DD of 92 %), acetonitrile (CHROMASOLV® gradient grade),85
bovine serum albumin, clotrimazole, glycerol, methanol CROMASOLV®, mucin from86
porcine stomach (type III, bound sialic acid 0.5 % - 1.5 %, partially purified) and sodium87
chloride were the products of Sigma-Aldrich, Chemie GmbH, Steinheim, Germany. Acetic88
acid (glacial), anhydrous potassium phosphate and sodium hydrogen phosphate were89
purchased from Merck KGaA, Darmstadt, Germany. Calcium hydroxide, glucose, lactic90
acid, potassium hydroxide, propylene glycol, sodium hydroxide and urea were obtained91
from NMD, Oslo, Norway. Ammonium acetate was the product of BHD Prolab, Leuven,92
Belgium.93
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2.1. Preparation of liposomes with clotrimazole95
Liposomes were prepared by the method described earlier (Berginc et al., 2014). In brief,96
clotrimazole (20 mg) and PC (200 mg) were dissolved in methanol in a round bottom flask.97
The solvent was evaporated using rotoevaporator system (Büchi rotavapor R-124 with98
vacuum controller B-721, Büchi Vac® V-500, Büchi Labortechnik, Flawil, Switzerland)99
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for at least 1 hour at 50 mm Hg and 40 °C. The remaining film was then re-suspended in 10100
mL of distilled water. If necessary, ultrasonic bath was used to completely dislodge the film101
from the flask. Liposomal suspensions were stored in the refrigerator (4-8 °C) overnight102
prior to further use.103
104
2.2. Vesicle size reduction105
Liposomes (4 ml) were transferred to a 10 mL beaker and placed on ice bath. The needle106
probe tip of probe sonicator was placed in the centre of the beaker containing liposomal107
suspension. The sonicator (Ultrasonic processor 500 watt, Sigma-Aldrich, St. Louis,108
Missouri, USA) was set to 40 % amplitude and the liposomes were exposed to ultrasonic109
irradiation for 1, 2 or 2x2 minutes, respectively. The sonicated liposomes were stored in the110
refrigerator for at least 6 hours prior to further use.111
112
2.3. Particle size analysis113
The particle size distributions of liposomes were determined by photon correlation114
spectroscopy (Submicron particle sizer model 370, Nicomp, Santa Barbara, California,115
USA). In order to avoid interference from dust particles, the test tubes to be used for the116
determination were filled with distilled water and sonicated for 10 min in ultrasonic bath,117
then rinsed with filtered water (using 0.2 µm filter) prior to the experiments. Small aliquots118
of the samples were diluted with the filtered water to obtain particle intensity of119
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approximately 200-350 kHz (di Cagno et al., 2011). All formulations were prepared in a120
laminar airflow bench and analyses run in vesicle mode and the intensity-weightdistribution121
at 23 °C. Three parallels were determined (run time 10 min) for each sample measurement.122
123
2.4. Zeta potential determination124
Zeta potential measurements were performed on a Malvern Zetasizer Nano Z (Malvern,125
Oxford, UK). To ensure the validity of the measurements, the instrument was calibrated126
throughout the measurements using the Malvern Zeta Potential Transfer Standard (−50 ± 5 127
mV). The liposomal suspensions were diluted in 1:40 ratio in filtrated water before128
measurements to achieve the proper count rate. All measurements were performed at 23°C129
and the results were expressed as the average of at least three independent samples.130
131
2.5. Entrapment efficiency determination132
To separate free from liposomally entrapped drug, the sonicated liposomes were133
ultracentrifuged (Beckman model L8-70M preparative ultracentrifuge with SW 60 Ti rotor,134
Beckman Instruments, Palo Alto, California, USA) for 30 minutes, at 10 °C and 85 000 g.135
The pellet (containing unentrapped drug and liposomes larger than 200 nm) was separated136
from the supernatant (smaller liposomes containing clotrimazole), re-suspended in 500 µL137
of distilled water and finally diluted to 2 mL with methanol. Drug content in both138
supernatant and pellet was determined by the HPLC method. A reversed phase column139
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(XTerra® RP18 5µm, 3.9 x 150 mm column, Waters, Dublin, Ireland) installed in a Waters140
e2795 Separations Module coupled with a Waters 2489 UV/VIS detector was used in the141
measurements. The mobile phase consisted of acetonitrile and MilliQ water in a gradient142
starting at 30% acetonitrile (A), increasing to 90% A over 10 minutes, then to 100% A after143
11 minutes. The HPLC measurements settings were as follows: flow rate 1 mL/min,144
column temperature of 25 °C, sample temperature 25 °C, injection volume 20 µL, run time145
11 min and the detection wavelength 210 nm. The correlation coefficient was 0.9997 and146
the minimum detectable amount of clotrimazole 0.5 μg/mL. The entrapment was expressed 147 




An enzymatic assay was used to determine the amount of lipid present in liposomes in152
order to calculate the entrapment efficiency. For this purpose a commercial test kit153
(Phospholipids B; Wako Chemicals USA, Inc., Richmond, Virginia, USA) was applied in154
the method described earlier (Basnet et al., 2012). Measurements were performed in155
triplicates.156
157
2.7. Coating of liposomes158
The chitosan solutions (0.1, 0.3 and 0.6 %, w/v) used for liposome coating were prepared in159
0.1 % and 0.5 % (v/v) glacial acetic acid, respectively. The chitosan solution was added160
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drop-wise to an equal volume of liposomes free from unentrapped clotrimazole, under161
controlled magnetic stirring at room temperature for 1 hour, followed by incubation in the162
refrigerator overnight. The rate of stirring was kept constant for all preparations (Karn et163
al., 2011).164
165
2.8. In vitro release study166
Drug release was followed by the method described earlier (Hurler et al., 2012). The Franz167
cell manual diffusion system (Perme Gear Ink, Diffusion cells and Systems, Hellertown,168
USA) was properly cleaned with methanol, demineralized water and distilled water,169
respectively. The heating circulator (Julabo Laboratechnik, F12-ED, Seelback, Germany)170
was set to 37 °C. The acceptor chamber (12 mL) was filled up with acetate buffer (pH 4.6;171
77.1 g of CH3COONH4, 70 mL of glacial acetic acid and distilled water up to 1000 mL).172
Cellophane membrane (Max Bringmann KG, Wendelstein, Germany) was pre-soaked in173
the same buffer. Liposomal samples (both chitosan-coated and non-coated and sonicated174
for 2x2 min) or controls (clotrimazole in propylene glycol) were added in the donor175
chamber and the system was properly sealed. The drug content in all tested samples was176
determined (HPLC) prior to the study and the volumes of formulations in donor chambers177
normalized to assure the same drug amount. The samples (500 µl) were collected after 1, 2,178
3, 4, 8 and 24 hours. The samples were replaced by an equal volume of buffer upon179
removal of sample from the acceptor chamber. The drug content was determined by the180
HPLC method. The experiments were performed in triplicates.181
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2.9. Preparation of vaginal tissue183
The sheep vaginal tissue (from pregnant animals) was obtained from the Laboratory184
Animal Centre, University of Oulu, Finland. The vaginal tissue was carefully removed185
from the underlying tissue and cleaned with the physiological solution (pH 7.4). Adequate186
sized pieces were moisten by 0.9 % (w/w) NaCl and packed in clinging film, and frozen (-187
20 °C). They were left to defrost at room temperature for at least 2 hours prior to188
experiments. The thickness of the tissue was determined to be ranging from 900 to 1140189
microns. It was earlier confirmed that no significant differences were observed in using190
fresh or snap-frozen tissue samples (Sassi et al., 2004). We have earlier also compared the191
barrier properties of the fresh vaginal tissue and frozen (-20 °C) and thawed tissue (both192
animal skin and vaginal tissue) and have not observed any difference in the properties.193
194
2.10. Ex vivo penetration study195
The defrosted vaginal tissue was cut to fit the Franz diffusion cells surface (1.77 cm2). The196
acceptor chamber was filled up with phosphate buffer (pH 7.4, 8 g/L NaCl, 0.19 g/L197
KH2PO4, and 2.38 g/L Na2HPO4) and the vaginal tissue fixed between donor and acceptor198
chamber. Samples (600 µL) were added into the donor cells and the system was properly199
sealed. The amount of the drug in each cell was the same, as confirmed by the HPLC200
analysis. Samples of 500 µL were collected at 1, 2, 3, 4, 8 and 24 hours and replaced with201
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an equal amount of buffer. Drug content was determined by the HPLC method. The202
measurements were performed in triplicates.203
204
2.11. In vitro mucin-binding test205
The mucoadhesion was measured by determining the binding of liposomes to pig mucin.206
Liposomes (1 mL) were mixed with equal volume of pig mucin (PM) suspension (400207
μg/mL) in 0.05 M PBS (pH 7.4) and incubated at room temperature for 2 hours, followed 208 
by ultracentrifugation for 1 hour, at 10 °C at 216 000 g (Optima LE-80; Beckman209
Instruments, Palo Alto, USA). Aliquots of 200 µL (4 from each sample) of the supernatants210
(free PM) were transferred to a microtitre plate (Costar® UV 96-well plate with UV211
transparent flat bottom, Acrylic, Costar®, Corning, New York, USA) and measured212
spectroscopically at 251 nm (Microtitre plate reader; Spectra Max 190 Microplate,213
Spectrophotometer Molecular devices, Sunnyvale, California, USA). The PM binding214
efficiency was calculated according to Naderkhani et al. (2014).215
216
2.12. Statistical evaluation217
The student’s t-test was used for comparison of two means. A significance level of p<0.05218




3. Results and Discussion222
In order to achieve optimal therapeutic outcome, the delivery system is expected to provide223
a sufficient amount of the active ingredient (in our case clotrimazole) at the desired site of224
action (vaginal mucosal tissue) for a sufficiently long period of time to enable drug to225
perform its therapeutic action. Therefore, in the first step in optimization of chitosan-coated226
liposomes for topical vaginal delivery, we were focusing on the relationship between227
encapsulation yields vs particle size. Smaller particles are expected to provide larger228
surface area, however those particles carry less clotrimazole load, whereas larger particles229




Liposomes have been studied as drug delivery systems for almost 5 decades. A number of234
liposomes-based products are on the market and many more are in pipelines (Allen and235
Cullis, 2013). We have previously reported on the potential of liposomes to enhance the236
anti-inflammatory properties of associated curcumin destined for vaginal therapy (Basnet et237
al., 2012). Guided by those promising results, we selected liposomes as carrier for238
clotrimazole and used chitosan-coating to i) assure prolonged and controlled release of239
clotrimazole and ii) assure its retention at vaginal site, without significant penetration240
through the vaginal tissue.241
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Size and size distribution of liposomes are important characteristics of liposomes destined242
for topical drug delivery. The effect of liposomal size on the efficacy of liposomal delivery243
to skin is rather well studied (Cevc, 2004); however, relatively little is known about the244
effect of vesicle size on the delivery of drugs intended for mucosal targeting at vaginal site.245
Takeuchi and co-workers (2001) have found that the amount of liposomes penetrating into246
the intestinal mucous layer increased when the size of the liposomes was reduced to247
approximately 100 nm for both non- and chitosan-coated liposomes. In previous248
experiments (Berginc et al., 2012) we observed that curcumin in smaller vesicles penetrated249
less into the upper layers of vaginal tissue as compared to curcumin in mulitilammelar250
vesicles. Both types of liposomes exhibited better tissue retention as compared to curcumin251
in solution form. Similarly, polymer nanoparticles smaller than 200 nm were reported to252
successfully deliver small-interfering RNA and provided sustained gene silencing253
throughout the female reproductive tract for at least 14 days (Woodrow et al., 2009).254
The particle size shown in Table 1 indicates that the liposomes sonicated for 2x2 minutes255
were in the desired size range. Liposomal dispersions exhibited two distinguished peaks in256
distributions, indicating bimodal distribution and rather high polydispersity (Table 1). With257
the increase in sonication time, the polydispersity index values decreased, as expected258
(Table 1).259
We tried to minimize the exposure of liposomes to the sonication force, as it is known that260
extensive sonication can lead to the release of originally incorporated drug and lipid261
degradation (di Cagno et al., 2011).262
Due to highly lipophilic nature of clotrimazole (log P of 3.5), clotrimazole was dissolved in263
the organic solvent together with lipid during the preparation of liposomes and was264
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expected to incorporate itself within lipid bilayers of liposomes. We observed similar265
entrapment efficiencies for liposomes sonicated for 1 and 2 minutes, and the loss of266
originally entrapped clotrimazole was remarkable only after sonication for 2x2 minutes,267
resulting in smaller liposomes (Table 1). In comparison to literature data, our entrapment268
(up to 22 μg clotrimazole/mg lipid) was found to be lower; however none of the published 269 
articles describes the use of the same liposome preparation method and phospholipid270
composition. Although Ning et al. (2005) reported a very high entrapment of clotrimazole271
(over 90 %) using the film method in preparation of liposomes, they used dialysis to272
separate unentrapped from liposomal drug. The fact that clotrimazole has aqueous273
solubility of only 5.5 μmol/L (Mw 344) (Bilensoy et al, 2006), and that no data is available 274 
on whether or not the sink conditions were assured in the experimental set up of Ning and275
coworkers (2005), it might be possible that part of the drug was accumulated in the276
dialysis-tube in a form of precipitates, falsely contributing to high entrapment values.277
Liposomes prepared by the proliposome and polyol dilution methods were reported to278
incorporate more clotrimazole (Pavelić et al., 1999; Pavelić et al., 2005); however, the 279 
methods of preparations differed from the method used in our experiments, and, more280
importantly, the vesicle size was larger than in our case. Proliposome method is known to281
yield multilamellar liposomes thus enabling high incorporation of lipophilic drug (Pavelić 282 
et al., 1999). An additional difference between the previous and current experiments was283
the liposomal composition (Pavelić et al., 2005). We choose to prepare liposomes from a  284 
simple lipid mixture to be able to follow the effect of chitosan coating in a rather285
straightforward manner, avoiding the interference of possible ionic interactions between286
lipid and chitosan and consequently mucin.287
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The coating of liposomes is expected to result in an increase in their original size289
(Filipović-Grčić et al., 2001; Karn et al., 2011). Although the entrapment of clotrimazole 290 
was lower than we have desired, considering that the obtained vesicle size was in the291
optimal range for the purpose of development of mucoadhesive liposomal delivery system,292
we proceeded with coating of those vesicles. Prolonged retention time would be a rationale293
for lowering the dose needed to induce antifungal effect; therefore lower drug load should294
not limit the applicability of the system.295
296
3.2. Coating of liposomes297
It is well established that the polymer concentration significantly influences the strength of298
mucoadhesion. Moreover, the optimal polymer concentration depends on the physical state299
of the delivery system (Andrews et al., 2009) and, in the case of coated liposomes; the300
liquid nature of the system needs to be taken into consideration. Therefore, we have used301
three different concentrations in the coating of liposomes, all resulting in liquid302
formulations. The coating resulted in an increase in particle size (Table 2), in agreement303
with the results reported by Karn and colleagues (2011) and Gradauer and coworkers304
(2012). The coating of liposomes with chitosan also resulted in an increase of liposome zeta305
potential (Table 2) in agreement with Berginc et al. (2014). Moreover, the pH of liposomal306
suspensions changed upon coating; non-coated liposomal suspensions had a pH of 6.0307
whereas 0.1, 0.3 and 0.6 % coated liposomal suspensions had a pH of 4.12, 4.02 and 4.07,308
respectively. This would represent additional advantage of chitosan-coated liposomes; it is309
well known that C. albicans adheres to vaginal tissue with higher affinity at pH 6 than at310
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pH 4 and that acidic formulations also restore the physiological acid pH of vagina (Chang311
et al., 2002).312
It was previously reported that the amount of polymer used for coating of nanoparticles and313
found on vesicle surface was similar regardless of the molecular weight of chitosan used314
(Llabot et al., 2011). However, nanoparticles coated with low molecular weight chitosan315
where found to be more bioadhesive than those coated with high molecular weight316
chitosan. This could be explained by the interpenetration mechanisms with the mucin317
chains, as it is known that long polymer chains reduce the interpenetration, reducing the318
bioadhesive strength (LLabot, 2011). This was the reason why we have selected low Mw319
chitosan as a coating material.320
321
Although there is no consensus on the optimal size range of nanocarriers expected to322
penetrate mucus layer, it was suggested that the nanocarriers in the size range of 200-500323
nm are superior to both much smaller and also larger nanosystems (das Nevas et al.,324
2011b). Takeuchi et al. (2005) confirmed the superiority of nanosize chitosan-coated325
liposomes in prolonging the retention time in the intestinal mucosa as compared to larger326
vesicles. However, the vaginal mucosa has unique features which make direct translation of327
the results rather difficult.328
329
Regarding the optimal size, it is also important to consider that some of the particles tend to330
agglomerate, and that agglomerates behave in a different manner than single particles (das331
Nevas et al, 2011a). We have tested our liposomes for one month stability (at 4 °C) and332
have not observed significant increase in the original size of chitosan-coated vesicles (data333
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not shown). It can be hypothesized that the chitosan-coating is working as a stabilizer by334
prohibiting agglomeration of the liposomes, even though the chitosan is not bound to the335
lipid surface either by covalent or ionic bonds. Although liposomes made of336
phosphatidylcholine have no surface charge, the electrostatically driven binding of chitosan337
to the lipid membrane is energetically favoured, even for neutral liposomes, leading to338
further stabilization of the vesicle suspension, as reported recently (Mertins et al., 2010;339
Mertins et al., 2011).340
341
3.3. In vitro release of liposomally-associated clotrimazole342
There are several means to achieve the prolonged release of drugs destined for vaginal343
administration. Most of the approaches rely on the use of polymer in a form of hydrogel, to344
assure both prolonged release and intimate contact between drug and vaginal mucosa,345
simultaneously using liposomes as solubilizers for poorly soluble drugs (Pavelić et al., 346 
2005). Other approaches use the complexation of drug with cyclodextrine, followed by347
incorporation of a complex in a hydrogel, such as for example Pluronic thermosensitive gel,348
exhibiting prolonged release of clotrimazole when the drug was complexed with β-349 
cyclodextrine prior to inclusion into the hydrogels (Bilensoy et al., 2006).350
We have followed the release of liposomally-associated clotrimazole (Figure1) in351
comparison to clotrimazole in a free form (propylene glycol as vehicle). All liposomal352
formulations exhibited prolonged release as compared to free drug (control). All353
formulations, even the control, also failed to release all of the incorporated clotrimazole,354
which may be explained by the fact that clotrimazole, a very hydrophobic molecule, has355
very limited solubility in water. In the case of the control (propylene glycol), an osmotic356
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effect was observed drawing water from the acceptor medium into the sample in donor357
chamber. As a consequence, clotrimazole started to precipitate (in donor chamber) when a358
critical amount of drug dissolved in propylene glycol is mixed with water. Therefore, we359
assume that it would be necessary to add some sort of the solubilizing agent into the360
acceptor medium (acceptor chamber) to secure sink conditions. The limitation of Franz361
diffusion system is the limited volume which can be used in the acceptor chamber, causing362
the problems for the poorly soluble drugs. However, we could detect the differences363
between control (free drug) and the drug released from liposomes. Although we have364
expected the slowest release from chitosan-coated liposomes, interestingly, the slowest365
release of the drug was perceived from non-coated (plain) liposomes (p<0.05). Non-coated366
liposomes act as solubilizer for clotrimazole in the lipid membrane and drug only diffuses367
from the lipid membrane as liposomes become leaky, if not coated. It seems that the368
partitioning of clotrimazole between outer aqueous medium and liposomal bilayers is in369
favour of liposomal bilayers, whereas in coated liposomes the release is supported by the370
presence of chitosan coating. We have also observed the difference in the release from371
liposomes coated with three different concentrations of chitosan; those coated with higher372
concentration of chitosan exhibited more pronounced sustained release, however not on a373
significant level. Chitosan is hydrophilic in nature and makes the surface of liposomes less374
hydrophobic, as in chitosan-coated liposomes. The thicker coatings (0.3 and 0.6 %, w/v,375
respectively) will cause the diffusion obstacle for the drug released from the surface,376
resulting in the slower release. Berginc et al. (2014) reported that increasing the amount of377
chitosan in the liposomal coating had no beneficial effect on the permeability of378
liposomally-associated curcumin. This is very interesting, and could be relevant for379
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different types of mucoadhesive coatings on the surface of various nanoparticles and380
requires further studies. This finding is in agreement with report by Fang and colleagues381
(2001) who proposed that even the lowest chitosan mole fraction is able to reduce the382
cooperative unit of the DPPC bilayer and lead to certain degree of membrane bilayer383
perturbation. Reduction of pH increased the number of protonated amines on the chitosan384
backbone and caused further disruption on the membrane organization. Although we have385
used different lipid in our experiments, the interactions between chitosan and polar head of386
phospholipids are well established (Mertins et al., 2010, 2011). Whether the observation we387
made for chitosan-coated liposomes incorporating clotrimazole would also apply for388
liposomally-entrapped hydrophilic drugs and for liposomes of various phospholipid389
compositions remains to be determined.390
391
3.4. Ex vivo penetration of liposomally-associated clotrimazole392
The mucoadhesive properties of chitosan are mostly result of its cationic character.393
Mucoadhesion of chitosan-based delivery systems can therefore be achieved through ionic394
interactions between the cationic primary amino groups of chitosan and the anionic395
substructures of the mucus. In addition, the hydrophobic interactions might contribute to its396
mucoadhesive properties (Bernkop-Schnürch and Dünnhaupt 2012). Although thiolated397
chitosans have stronger mucoadhesive properties than non-modified chitosan, their398
compatibility with vaginal environment remains to be proven, and we have therefore opted399
for non-modified chitosan as a coating material. Chitosans of high degree of deacetylation400
and of a high molecular mass were reported to cause an increase in the epithelial401
permeability (Bernkop-Schnürch and Dünnhaupt, 2012), which needs to be taken into402
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consideration when choosing the type of chitosan for the coating of liposomes intended for403
administration into pregnant patients, and was the reason that we selected low molecular404
weight chitosan. We are currently evaluating the system in the in vivo conditions in405
pregnant sheep to confirm the safety and non-irritability of the system, as it is well-known406
that vaginal irritation can lead to increased susceptibility to foreign pathogens and407
inflammation.408
Mucus is a viscous coating on many epithelial surfaces and consists mainly of water (up to409
95 % weight), inorganic salts, carbohydrates, lipids and glycoproteins, termed mucins.410
Mucins are hydrosoluble and responsible for the gel-like properties of the mucus (Serra et411
al., 2009). In order for mucoadhesion to take place, the wetting and swelling of polymer412
should enable an intimate contact with the mucosal tissue, followed by interpenetration of413
the polymer chains and entanglement between the polymer and mucin chains. Chitosan414
exhibits strong bioadhesive properties through the electrostatic interactions with sialic415
groups in mucins of the mucosal layer. The high positive charge density of chitosan416
enhances its mucoadhesiveness (Meng et al., 2011). It is also important to consider the417
concentration of liposomes applied to vaginal tissue, as this may affect the normal structure418
of mucus and cause the collapsing of mucin fibres (das Nevas et al., 2011b). The419
concentration of liposomes used in our experiments was low and not expected to cause420
changes in mucosal structure and was considered to be safe. However, it remains to be421
evaluated in the in vivo studies in suitable animal model.422
423
Although the mucoadhesive behaviour of bulk material such as polymer-based hydrogels424
made of chitosan for example is well characterized, rather little is known about the425
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behaviour of chitosan at the nanoscale (das Nevas et al., 2011b). We have previously426
confirmed the bioadhesion potential of chitosan-based hydrogels onto the skin (Hurler and427
Skalko-Basnet, 2012); however, the bioadhesiveness of chitosan-coated liposomes in428
nanosize range cannot be directly compared to hydrogels.429
430
We have used the vaginal tissues of pregnant sheep to mimic closer the in vivo evaluation431
of our formulation in pregnant animals. The results presented in Figure 2 indicate that432
liposomes are able to retain associated clotrimazole on the vaginal tissue and in the tissue,433
thus preventing undesired penetration through the vaginal tissue. This is of great434
importance considering clotrimazole therapy in pregnant patients. The free drug, a form of435
propylene glycol solution, penetrated through vaginal tissue in remarkable manner (almost436
40 % after 24 hours), whereas the liposomally-associated drug penetrated to significantly437
lower extent (p<0.01). We are aware that propylene glycol is a known skin penetration438
enhancer and acts as a carrier-solvent for poorly soluble substances such as clotrimazole.439
Moreover, propylene glycol may induce the osmotic effects which result in the changed440
barrier properties of the tissue. However, due to a very low solubility of clotrimazole, the441
choice of a solvent which we could use to prepare clotrimazole solution was very limited.442
Most of the other solvents are expected to directly damage the barrier properties of the443
vaginal tissue, resulting in the even higher penetration.444
In respect to the drug retention on and within vaginal tissue, It appears that liposomes445
coated with 0.1 % chitosan solution exhibited lowest penetration of clotrimazole and446
highest amount of clotrimazole retained on top of the tissue (Figure 2), both in comparison447
to plain, non-coated liposomes and liposomes coated with different polymer concentrations.448
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One has to consider that the increased retention time on the target site would outweigh449
more sustained release from non-coated liposomes (Figure 1), as reported for mucoadhesive450
liposomes incorporating curcumin (Berginc et al., 2014).451
The vulovaginal candidosis is characterized by the infection reaching the deeper epithelial452
layers (das Nevas et al., 2008); thus prolonged retention time on the vaginal mucus would453
be beneficial. To confirm that chitosan coating on liposomal surface is available for close454
interaction with mucin, we tested non-coated and coated liposomes for mucin-binding455
potential (Figure 3). The results clearly indicate (p< 0.01) that liposomes coated with 0.1 %456
polymer concentration exhibit superior interaction with mucin in comparison to all other457
formulations. This indicates that they exhibit potential to retain at the vaginal site. This type458
of liposomes may improve the effectiveness of model drug, yet prevent the undesired459
systemic absorption.460
461
It is expected that lipophilic substances/drugs are absorbed from vagina as administration462
site through the transcellular pathway (Sassi et al., 2004). The passive diffusion was found463
to be the main mechanism of curcumin penetration into vaginal mucosa when liposomally-464
associated curcumin was tested in the ex vivo conditions. Our current findings are in full465
agreement. Depending on the liposomal size, the concentration of curcumin in different466
layers of vaginal tissue was found to be significantly higher as compared to concentration467
of curcumin applied in a form of solution. The permeability from 0.6 % chitosan-coated468
liposomes was found to be similar or even lower than from 0.1 % coated liposomes when469
tested in artificial and isolated bovine mucus. This can be explained by the fact that an470
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increase in the liposomal size, as well as changes in zeta potential, lead to the major part of471
the polymer being hindered in the deeper layers and unavailable for immediate adhesion.472
Only when the uppermost polymer sheets of higher polymer concentrations coatings are473
removed by erosion or by detachment from mucus, more chitosan becomes available for474
adhesion. This was proposed as an explanation for the superiority of liposomes coated with475
lower concentration of polymer (Berginc et al., 2014).In addition, liposomal curcumin476
administered vaginally exhibited negligible potential for systemic absorption, which would477
greatly support its administration in pregnant patients (Berginc et al., 2012) in agreement478
with our findings.479
480
Currently, there is a vivid discussion in the field of vaginal drug delivery whether the481
mucoadhesiveness of delivery system is advantageous for improved drug therapy or rather482
disadvantageous (das Neves et al., 2011a). The physical properties of mucus are complex483
and often described as non-Newtonian behaviour with properties between those of a484
viscous liquid and an elastic solid. In women with bacterial vaginosis, the viscosity of485
vaginal fluid is reduced, leading to increased risk of infections and reduced barrier486
properties of vaginal mucus (Lai et al., 2009). Nevertheless, there is a consensus that the487
nanocarrier should first be retained at the vaginal site to increase the residence time and488
avoid vaginal leakage, and subsequently migrate through mucus towards the mucosal489
surface (das Neves et al., 2012). Antifungal agents used to treat vaginal candidosis need to490
penetrate deep into the epithelium to reach invasive Candida hyphae and exert a local491
antifungal action (das Neves et al., 2008). One approach to achieve this purpose has been492
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recently suggested by our groups by using deformable propylene glycol liposomes (Vanić 493 
et al., 2014). Another approach is based on applying chitosan-based mucoadhesive494
liposomes developed in this study.495
Our findings clearly indicate that liposomes are a suitable drug delivery system in respect to496
both prolonged release and limited tissue penetration. Liposomes are able to assure497
sustained release of associated drug either with or without chitosan coating. However,498
coated liposomes are expected to prolong the residence time in the vaginal cavity in the in499
vivo conditions and are therefore, considered to be superior. The next step involves the500
determination of bioadhesiveness of the system by the modified method originally501
developed for skin (Hurler et al., 2012).502
We are aware of a need to address current limitations of experimental set up, such as that503
our experiments were performed on the vaginal tissue in the absence of cervicovaginal504
fluid. The reason that we did not use cervicovaginal fluid surrogate, is that it was reported505
that differences between the surrogate and native mucus may be noticeable. We also did not506
vary the pH of the donor medium, although it is known that the pH is affecting the transport507
across mucus (das Neves et al., 2012). The effect of semen and the changes in vaginal pH508
related to age and disease conditions remain to be evaluated.509
510
4. Conclusions511
Chitosan-coated liposomes were shown to exhibit prolonged release of associated512
clotrimazole. The penetration of liposomally-associated clotrimazole through the vaginal513
tissue was reduced as compared to non-coated liposomes, an important fact regarding514
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system’s potential in topical vaginal therapy, especially in pregnant patients. We are515
currently evaluating the system in the in vivo conditions in pregnant sheep to confirm the516
safety and non-irritability of the system as it is well-known that vaginal irritation can lead517
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Table 1: Liposomal characteristics (n=3)659






Figure 1: In vitro release of clotrimazole from coated and non-coated liposomes (n=3)666
The concentration of clotrimazole in all formulations was the same. Control (*) contained667
clotrimazole in propylene glycol; non-coated liposomes (**) were diluted to obtain the668
same concentration of clotrimazole as in coated liposomes.669
670
671
Figure 2. Ex vivo penetration studies (24 hours) in vaginal tissue (n=3)672
The concentration of clotrimazole was the same in all formulations. Control contained673
clotrimazole in propylene glycol; non-coated liposomes were diluted to obtain the same674
concentration of clotrimazole as in coated liposomes. Liposomal formulations assured675



























1 317 ± 47 56.8 40 ± 5 41.0 0.58 23.2 ± 2.5
2 234 ± 31 53.9 36 ± 5 43.8 0.46 25.0 ± 0.5
2x2 111 ± 16 83.1 29 ± 4 16.9 0.46 16.5 ± 4.5
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- 107 ± 3 54 ± 3 27 ± 3 46 ± 3 0.34 - 1.6 ± 0.2
0.1 135 ± 21 53 ± 6 42 ± 9 45 ± 5 0.29 25.9 ± 4.0
0.3 141 ± 6 64 ± 6 48 ± 5 35 ± 6 0.27 35.6 ± 1.9
0.6 190 ± 8 58 ± 6 54 ± 2 42 ± 6 0.29 43.8 ± 3.3
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